SERA SERA PROGNOSTICS, INC.
Services-Medical Laboratories · Nasdaq · SEC CIK 1534969 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.1%
TTM net income YoY-2.6%
TTM EPS YoY11.8%
Revenue 3-yr CAGR-33.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-38,755.2%
Net margin-34,866.7%
FCF margin-30,199.0%
EBITDA margin-37,922.9%
Returns
ROE-49.7%
ROA-35.6%
ROIC (approx.)-46.5%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets34.4%
Debt / equity0.00x
Current ratio1.88x
Interest coverage-5,315.00x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue508.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $42,000 | $30,000 | $14,000 | $10,000 | $16,000 | $17,000 | $38,000 | $24,000 |
| Cost of revenue | — | $50,000 | $42,000 | $42,000 | $41,000 | $41,000 | $40,000 | $32,000 |
| Gross profit | — | -$20,000 | -$28,000 | -$32,000 | -$25,000 | -$24,000 | -$2,000 | -$8,000 |
| R&D expense | $2.72M | $3.49M | $3.03M | $3.22M | $3.28M | $3.34M | $3.33M | $3.14M |
| SG&A expense | $3.89M | $4.25M | $4.29M | $4.04M | $4.08M | $4.14M | $4.44M | $4.01M |
| Operating income | -$8.89M | -$10.00M | -$9.36M | -$8.95M | -$8.98M | -$9.32M | -$9.25M | -$9.42M |
| Interest expense | $2,000 | $2,000 | $2,000 | $1,000 | $2,000 | $2,000 | $4,000 | $6,000 |
| Net income | -$8.05M | -$9.14M | -$8.40M | -$7.88M | -$7.81M | -$8.05M | -$8.19M | -$8.58M |
| EBITDA | -$8.69M | -$9.84M | -$9.17M | -$8.71M | -$8.78M | -$9.11M | -$9.03M | -$9.21M |
| EPS (basic) | -0.16 | -0.18 | -0.17 | — | -0.16 | -0.16 | -0.20 | — |
| EPS (diluted) | -0.16 | -0.18 | -0.17 | — | -0.16 | -0.16 | -0.20 | — |
| Weighted avg. shares (diluted) | 50.79M | 50.48M | 50.26M | — | 49.53M | 49.07M | 41.97M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.99M | $4.40M | $4.17M | $3.94M | $4.08M | $5.02M | $5.23M | $4.04M |
| Short-term investments | $40.10M | $42.05M | $43.23M | $35.26M | $39.22M | $35.14M | $40.97M | $42.19M |
| Receivables | $17,000 | $10,000 | $11,000 | $12,000 | $14,000 | $17,000 | $25,000 | $34,000 |
| Current assets | $46.22M | $48.13M | $49.73M | $40.77M | $44.49M | $40.87M | $47.28M | $47.60M |
| PP&E, net | $1.72M | $1.42M | $1.10M | $1.15M | $1.03M | $1.20M | $1.31M | $1.24M |
| Intangibles | $859,000 | $888,000 | $881,000 | $910,000 | $939,000 | $968,000 | $997,000 | $1.03M |
| Total assets | $79.98M | $86.74M | $93.54M | $101.93M | $108.12M | $111.83M | $118.18M | $72.58M |
| Current liabilities | $24.53M | $24.36M | $23.42M | $24.19M | $23.50M | $23.60M | $23.40M | $24.77M |
| Total liabilities | $27.54M | $27.36M | $25.92M | $26.52M | $25.94M | $23.60M | $23.40M | $24.77M |
| Shareholders' equity | $52.44M | $59.38M | $67.62M | $75.41M | $82.18M | $88.23M | $94.78M | $47.80M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.30M | -$6.31M | -$8.77M | -$6.12M | -$6.48M | -$5.47M | -$7.55M | -$6.26M |
| Capital expenditure | $134,000 | $16,000 | $8,000 | $330,000 | $112,000 | $281,000 | $3,000 | $8,000 |
| Free cash flow | -$7.43M | -$6.33M | -$8.78M | -$6.45M | -$6.59M | -$5.75M | -$7.56M | -$6.27M |
| Investing cash flow | $6.84M | $6.39M | $8.98M | $5.89M | $5.17M | $5.24M | -$44.80M | $7.38M |
| Financing cash flow | $48,000 | $140,000 | $20,000 | $93,000 | $373,000 | $18,000 | $53.54M | $234,000 |
| Depreciation & amortization | $200,000 | $162,000 | $193,000 | $244,000 | $200,000 | $208,000 | $216,000 | $211,000 |
| Stock-based compensation | $1.28M | $823,000 | $835,000 | $1.02M | $1.25M | $1.34M | $1.49M | $1.62M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.